Fast and compliant viral clearance solutions

For tissue-based devices, ensuring viral clearance is not just a regulatory hurdle, it’s a critical safeguard. But for many, especially those approaching submission for the first time, viral clearance studies can seem complex, time-consuming, and uncertain. The stakes are high, and you need to get it right. The Eurofins Medical Device Services network of laboratories is uniquely equipped to support you with consultancy on study design and virus selection. Our experts offer a powerful combination of in-depth regulatory knowledge, extensive viral safety experience, and state-of-the-art testing capabilities. Whether you’re validating your process or finalising submission, we can guide you through every step of your viral clearance programme.

Our dedicated viral clearance facility supports both GLP and non-GLP studies, following EN ISO 22442-3 and FDA guidance. We provide expert consultancy on study design, virus selection, and risk assessment. With a dedicated virus testing facility and extensive experience across a wide range of animal-derived matrices - including bone, tendon, cartilage, and liver - we design tailored studies that evaluate chemical and physical inactivation methods. Our virus panels are selected based on product-specific risk profiles and regulatory expectations, ensuring robust validation of viral removal or inactivation processes.

Backed by more than 15 years of viral safety expertise, our scientists ensure your viral clearance studies are efficient, effective, and regulatory ready. Whether you’re working with bovine, porcine, or other tissue-derived components, we offer practical, science-led strategies tailored to your product, process, and timeline.

Partner with our experts

Services

Three laboratory professionals in white lab coats and safety glasses standing together in a bright lab, reviewing a document with the Eurofins logo, engaged in discussion with equipment visible in the background.

Conduct non-GLP feasibility trials

To preliminarily evaluate virus inactivation rates, reducing time and cost.

Group of five laboratory professionals in white lab coats standing in a lab, facing the camera with arms crossed, with scientific equipment and workstations visible in the background.

Design and validate a scaled-down version

Of your manufacturing process under controlled laboratory conditions.

viral-clearance-planning

Identify potentially virus-inactivating steps

Within your manufacturing process through comprehensive literature review.

Professional wearing glasses and a white shirt seated at a conference table, turned toward the camera, with colleagues working on laptops in the background and the Eurofins branding visible on the wall.

Resolve challenges

Related to residual cytotoxicity and virus recovery for accurate and reliable results.

Two laboratory professionals in white lab coats reviewing a blue folder together in a laboratory setting, with additional lab equipment and a third professional working at an instrument station in the background.

Select test viruses

That are most relevant to your product and regulatory requirements.